1. Executive Summary

‍

Industry overview (macro + sector-specific)

Materials and chemicals are in that familiar spot where the fundamentals are steady enough to do deals, but nobody gets to pretend capital is cheap or the cycle is “handled.” Buyers are acting like grown-ups again. They want assets that strengthen the core, add defensible technology, or fix a portfolio gap. And they’re picky about cash flow quality.

Two big forces keep showing up across credible 2025 coverage. First, portfolio reshaping is still a major driver. Large chemicals groups are pruning complexity and leaning into fewer, clearer themes. Second, the megadeal is back, but only where the buyer has a real structural edge (feedstock, geography, integration, or a government-backed balance sheet). McKinsey’s energy and materials M&A work calls 2025 a return of the megadeal, with the Americas leading deal value and several platform-scale transactions re-emerging.

‍

Recent M&A momentum (deal count, value)

On volume, the post-2021 hangover is still visible. A PitchBook-based view summarized by Roland Berger shows deal counts across North America, Europe, and Asia peaking in 2021 and stepping down through 2024. North America, for example, went from 363 deals in 2021 to 225 in 2024; Asia from 189 to 140 over the same period. Europe is the interesting one: it’s down from 2021 highs, but 2024 actually ticks up versus 2023 in their dataset, which fits the “European restructuring and carve-out churn” narrative.

On specialty chemicals and advanced materials, Proventis reports 143 deals in H1 2025 with about €22bn of disclosed deal value. Their read is simple: volume cooled versus the strong Q4 2024 burst, but valuations stayed resilient, suggesting buyers are still willing to pay for the right assets even when the calendar looks quieter.

At a broader chemicals level, KPMG’s ENRC update points to fewer deals but a mix shift: H1 2025 chemicals deal volume was down 11.5% versus H2 2024 and down 12.7% YoY, while deal value was down versus H2 2024 but sharply higher YoY. That combination usually means fewer, bigger, more strategic transactions are doing the heavy lifting.

‍

High-level multiples & key trends

Public market anchors (useful as a sanity check when you’re triangulating private deal pricing) still show a clear split between commodity and specialty.

NYU Stern (Damodaran) sector data for January 2026 shows:

• Basic chemicals: EV/EBITDA 8.57x and EV/Sales 0.85x
  
  
• Specialty chemicals: EV/EBITDA 13.36x and EV/Sales 2.65x
  
  

Deals are typically pricing above public trading for quality specialty assets, especially when scarcity is real or a carve-out creates a clean “fix-it” runway. Proventis illustrates that gap directly in specialty chemicals and advanced materials: H1 2025 trading EV/EBITDA at 9.4x versus implied transaction EV/EBITDA at 15.7x (disclosed deals), a reminder that control plus synergy plus scarcity is still a potent cocktail.

One other useful lens: R.L. Hulett’s PitchBook-based specialty chemicals and performance materials update shows a recent normalization in sponsor pricing and a rebound in strategic pricing in 2025. Their reported 2025 median EV/EBITDA was 12.3x for private equity buyers and 10.3x for strategic buyers (after strategic medians dipped in 2024). The market’s message: sponsors are still underwriting carefully, strategics are paying up when the asset is genuinely on-strategy.

‍

Major players / consolidators

The most consistent consolidators tend to fall into four buckets:

1. Integrated and state-backed petrochemicals platforms
   These buyers can justify scale because they have feedstock advantages and often a longer strategic horizon. The headline example is ADNOC and OMV’s plan to build a $60bn+ polyolefins champion (Borouge + Borealis) and acquire Nova Chemicals at a cited $13.4bn enterprise value, with a stated synergy target around $500m annually.
   
   
2. Specialty chemicals leaders doing bolt-ons
   They’re not chasing “bigger” as much as “better”: higher-value niches, sticky customer relationships, and formulation/IP advantages.
   
   
3. Distribution consolidators
   Specialty distribution remains a classic roll-up lane when the buyer can win on supplier access, technical sales coverage, and working-capital discipline.
   
   
4. Private equity platforms and carve-out specialists
   As carve-outs persist, sponsors with integration muscle and operational teams have plenty of room to play, especially when the asset is separation-heavy but strategically clean.

‍

Summary of Key Metrics

‍

2. Industry M&A Market Overview

Deal activity trends (Y/Y and Q/Q)

The chemicals and materials deal tape has two stories running at once.

Story one is the longer cycle: post-2021 normalization. Roland Berger’s PitchBook-based tracking shows global chemicals M&A peaking in 2021 and declining steadily through 2024. In their regional cut, North America falls from 363 deals in 2021 to 225 in 2024, Asia from 189 to 140, and Europe lands at 198 in 2024, slightly above 2023. That small European uptick matters because it hints at continued portfolio reshaping and divestitures even when buyers are more cautious. (Roland Berger)

Story two is the short cycle: specialty chemicals and advanced materials are still trading, just not at the frantic pace of late 2024. Proventis reports 143 deals in H1 2025 (about 20% fewer than H2 2024), with roughly €22bn of disclosed deal value. Said differently, deal flow cooled, but the market didn’t shut. (Proventis)

If you want an extra cross-check outside those datasets, multiple advisory sector updates from 2024–2025 describe the same pattern: fewer processes coming fully to market, more “quiet” conversations, and a heavier skew toward carve-outs and targeted bolt-ons rather than broad consolidation sprees. (Piper Sandler, Harris Williams)

‍

Notable megadeals

The return of the megadeal is real, but it’s selective and concentrated in advantaged platforms.

McKinsey’s February 13, 2026 energy and materials M&A review calls out a 2025 rebound in deal value and renewed momentum from megadeals and joint ventures. It’s a useful framing because it captures why some very large materials-linked deals are happening even while mid-market volume remains choppy. (McKinsey & Company)

Representative platform-level example you can point to in materials-linked chemicals: large integrated and state-backed players building global polyolefins scale (often via JVs and combinations rather than simple one-step acquisitions). The strategic logic is typically footprint + integration + feedstock edge, with synergies and procurement/optimization levers as the value creation engine. (McKinsey & Company)

‍

Private equity vs. strategic acquirer share

Private equity is behaving like it has a return hurdle again. That’s not a bad thing. It’s why the sponsor bid is often strongest where (a) there’s a carve-out complexity discount, (b) operational improvement is tangible, and (c) the asset can support leverage without living on a prayer.

Two data-backed signals:

• McKinsey notes rising private equity activity as part of the 2025 rebound in energy and materials dealmaking. (McKinsey & Company)
  
  
• R.L. Hulett’s PitchBook-based specialty chemicals and performance materials update shows PE deal multiples normalizing in 2024–2025 and comments on selectivity, especially versus the prior-cycle froth. (RL Hulett)
  
  

Strategics, meanwhile, are more willing to pay up when the asset is truly on-strategy (technology, mix upgrade, regional adjacency, or direct synergy capture). In the same R.L. Hulett dataset, strategic median EV/EBITDA rebounds in 2025 versus 2024, which is consistent with “fewer deals, but higher conviction.” (RL Hulett)

‍

Capital availability

Capital is available, but it’s not forgiving. Buyers are underwriting with more attention to:

• Where the cycle is (and whether EBITDA is normalized or peak-y)
  
  
• Working capital behavior (inventory swings can wreck a year of “synergies”)
  
  
• Separation costs and stranded overhead in carve-outs
  
  

Roland Berger highlights valuation gaps and misalignment around normalized EBITDA as a key driver of process failure in 2024, which is a fancy way of saying buyers and sellers often couldn’t agree what earnings should look like in a normal year. (Roland Berger)

‍

M&A Volume/Value by Year

Map of Global Deal Hotspots

‍

3. Valuation Multiples & Comps

Median EV/Revenue, EV/EBITDA by sub-sector

In chemicals, “one multiple” is a trap. The spread between basic and specialty is structural, and it shows up in both trading comps and deal prints.

Public market anchors (US, January 2026)
NYU Stern (Damodaran) publishes sector valuation multiples using data from multiple services. As of January 2026, the medians are:

• Chemical (Basic): EV/EBITDA 8.57x
  
  
• Chemical (Specialty): EV/EBITDA 13.36x (Pages at Stern, Pages at Stern)
  
  

That 4–5 turn gap is the market’s way of saying: predictable margins, pricing power, and differentiated formulations get paid. Commodity spread exposure usually doesn’t.

Deal market medians (specialty/performance materials)
R.L. Hulett’s Specialty Chemicals & Performance Materials update (PitchBook-reported deals) shows 2025 medians at:

• Private equity: 12.3x EV/EBITDA (down from 13.8x in 2024)
  
  
• Strategic: 10.3x EV/EBITDA (up from 8.2x in 2024) (RL Hulett)
  
  

A useful read-through: sponsors cooled a bit after a hot 2023–2024 stretch, while strategics re-engaged on the right assets in 2025.

‍

Historical multiple ranges (3–5 year view)

There are two “histories” you should look at: public market cycles and private deal clearing levels.

Public market ranges
Sector EV/EBITDA tends to move with:

• Earnings visibility (cycle confidence)
  
  
• Cost of capital (rates/credit spreads)
  
  
• Forward margin expectations (energy/feedstock, pricing)
  
  

A common way to show this cleanly is a simple line chart for sector EV/EBITDA over time (Materials vs S&P 500). Siblis Research publishes a time series view of EV/EBITDA multiples by sector and emphasizes using current vs historical averages to judge whether a sector looks rich or cheap relative to itself. (Siblis Research)

Private deal clearing levels
R.L. Hulett’s reported medians give you a handy 2022–2025 spine for sponsor vs strategic paid multiples in specialty chemicals/performance materials. The eye-catcher is 2023 (PE median spiking), followed by normalization into 2024–2025 and a strategic rebound in 2025. (RL Hulett)

‍

Comparison to S&P 500 / related industries

If your reader is a generalist (or a CFO who still benchmarks everything to the S&P), the simplest comparison is:

• Materials generally trades at lower EV/EBITDA multiples than many growth-heavy sectors, and often below the broad market at points in the cycle, because cyclicality and capex intensity are always in the room.
  
  

For a practical cross-sector comparison slide, you can pair:

• Materials EV/EBITDA trend line (Siblis)
  
  
• Chemicals sub-sector medians (Damodaran basic vs specialty)
  …and it tells the story without drowning the audience in noise. (Siblis Research, Pages at Stern)

‍

Historical Valuation Multiples

Comps Table: Peer Multiples & Financials

‍

4. Top Strategic Acquirers & Investors

If Section 3 was about price, Section 4 is about intent. Who’s buying — and why — tells you more about where the sector is headed than any single multiple.

Over the last 12–24 months, materials and chemicals M&A has clustered around three clear buyer profiles:

1. Platform builders with feedstock or structural cost advantage
   
   
2. Specialty consolidators upgrading mix and margin
   
   
3. Private equity funds leaning into carve-outs and operational turnarounds
   
   

Below is a structured look at the most active and strategically relevant acquirers, followed by their investment theses.

‍

Top Strategic Acquirers (Recent Activity Focus)

The following buyers have been visibly active in materials and chemicals transactions, supported by public disclosures and market reporting:

Strategic / Industrial Buyers

1. ADNOC / XRG
   High-profile platform activity including the agreement involving Covestro and broader polyolefins consolidation initiatives with OMV. These transactions reflect a long-term feedstock and scale strategy.
   Source: Covestro investor materials; ADNOC releases.
   
   
2. OMV
   Engaged in combination activity aimed at building a global polyolefins platform with ADNOC. The logic is global scale, integration, and portfolio repositioning.
   
   
3. BASF (Portfolio reshaping)
   Entered into agreement to sell a majority stake in its coatings business to Carlyle and QIA (EV €7.7bn), reflecting focus sharpening and capital redeployment.
   Source: BASF press release.
   
   
4. Sherwin-Williams
   Acquisition of BASF’s Brazilian decorative paints business (Suvinil), strengthening LATAM coatings footprint.
   
   
5. Covestro
   Bolt-on acquisition of Pontacol (specialty films), reinforcing higher-value specialty exposure.
   
   
6. Honeywell
   Acquisition of Johnson Matthey’s catalyst technologies unit (~£1.8bn EV), expanding process and automation adjacency.
   
   
7. IMCD
   Ongoing specialty chemicals distribution consolidation (e.g., Apus Química acquisition).
   
   
8. Air Products
   Continued capital deployment in industrial gases and energy-transition-linked assets.
   
   
9. Linde
   Selective capital projects and disciplined M&A in industrial gases.
   
   
10. Celanese
    Portfolio repositioning toward engineered materials and specialty intermediates.
    
    

Private Equity Platforms (Active in Carve-Out & Specialty Segments)

1. Carlyle
   Majority stake acquisition in BASF coatings business; classic carve-out value creation case.
   
   
2. Qatar Investment Authority (QIA)
   Co-investor alongside Carlyle in BASF coatings.
   
   
3. Advent International
   Historically active in specialty chemicals carve-outs and industrial restructuring.
   
   
4. Apollo Global Management
   Known for industrial carve-outs and complex separations across sectors.
   
   
5. Bain Capital
   Active in chemicals distribution and specialty segments.
   
   

Investment Theses: Why They’re Acquiring

Feedstock Advantage + Platform Scale
Integrated oil and petrochemical players are building scale platforms that combine geographic footprint with advantaged feedstock. The value creation lever is structural cost advantage plus procurement and integration synergies. The ADNOC/OMV initiatives fall squarely in this bucket.

Portfolio Optimization
Large diversified players (e.g., BASF) are exiting subscale or less-core segments to simplify strategy, reduce earnings volatility, and redeploy capital into higher-return areas.

Specialty Mix Upgrade
Buyers like Sherwin-Williams, Covestro, and Honeywell are targeting assets that improve margin stability, deepen customer integration, or enhance technology differentiation.

Carve-Out Operational Arbitrage
Private equity is focused on businesses where standalone execution, pricing discipline, and working capital improvement can drive value independent of multiple expansion.

Distribution Roll-Ups
IMCD and similar distributors continue consolidating fragmented specialty chemicals distribution, where supplier access and technical sales coverage create defensible positions.

‍

Logo Grid: Active Acquirers

Deals by Acquirer, Value, Rationale

‍

5. Transaction Case Studies

Below are four deals that capture what is actually happening in materials and chemicals right now: platform scale plays, carve-outs, and high-value technology assets. Each snapshot is written like a one-page you could drop into a deck.

‍

Case study 1: Honeywell acquires Johnson Matthey’s Catalyst Technologies

Snapshot

• Announcement date: May 22, 2025 (Honeywell, matthey.com)
  
  
• Buyer: Honeywell
  
  
• Seller: Johnson Matthey
  
  
• Asset: Catalyst Technologies business
  
  
• Deal size: £1.8bn enterprise value, all-cash (Honeywell, matthey.com)
  
  
• Timing: expected completion in the first half of calendar year 2026 (per seller) (matthey.com)
  
  

Strategic rationale

• Extends Honeywell UOP’s catalyst and process technology offering, with added installed base and stronger positioning in refining, petrochemical, and renewable fuels applications. (Honeywell)
  
  
• Fits the broader “more recurring aftermarket” angle: catalysts plus process tech tends to create long, sticky customer relationships. (Honeywell)
  
  

Multiple paid

• Honeywell states the transaction represents approximately 11x estimated 2025 EBITDA, inclusive of tax benefits and run-rate cost synergies. (Honeywell)
  
  
• Johnson Matthey describes the valuation as 13.3x EBITDA (based on its presentation of the metric). (matthey.com)
  Practical takeaway: the headline multiple depends on how each side defines EBITDA and synergy/tax treatment. That difference is normal in real deal math.
  
  

Synergies and value creation levers

• Honeywell highlights anticipated synergies across UOP and Honeywell Process Solutions, with benefits from Honeywell’s aftermarket capabilities. (Honeywell)
  
  
• The real underwriting usually comes down to: attach rate on services, catalyst lifecycle economics, and cross-selling process automation into the installed base.
  
  

Integration watch-outs

• Customer retention risk during integration
  
  
• Managing technical talent and R&D continuity
  
  
• Timing of synergy capture versus integration costs
  
  

Case study 2: BASF Coatings carve-out to Carlyle and QIA

Snapshot

• Announcement date: October 10, 2025 (basf.com)
  
  
• Buyer: funds managed by Carlyle, partnered with Qatar Investment Authority (QIA) (basf.com)
  
  
• Seller: BASF
  
  
• Asset: automotive OEM coatings, automotive refinish coatings, and surface treatment businesses (basf.com)
  
  
• Deal size: €7.7bn enterprise value (basf.com)
  
  
• Expected close: Q2 2026, subject to regulatory approvals (basf.com)
  
  

Strategic rationale

• For BASF: portfolio focus and capital recycling. The company is effectively turning a business line into a more self-standing story. (basf.com)
  
  
• For Carlyle/QIA: classic carve-out value creation. Standalone setup plus procurement, footprint, overhead, and working capital levers.
  
  

Multiple paid

• EV/EBITDA was not disclosed in the press release. (basf.com)
  If you want to estimate an implied multiple, you would need a clean LTM EBITDA for the carved asset and adjust for separation costs.
  
  

Synergies and value creation levers

• This is less about “synergies” and more about operational levers:
  
  
  
  • Standalone cost structure reset
    
    
  • Working capital discipline
    
    
  • Pricing governance and mix management
    
    
  • Targeted capex and footprint decisions
    
    

Deal-specific risks

• Separation complexity: systems, shared services, stranded costs
  
  
• Cyclic exposure: automotive production and refinish demand cycles
  
  
• Standalone governance: how quickly the new organization can run independently
  
  

Case study 3: ADNOC and OMV platform build plus Nova Chemicals acquisition

Snapshot

• Announcement date: 2025 (framework announcement in the linked release) (ADNOC, omv.com)
  
  
• Parties: ADNOC and OMV
  
  
• Assets: combination of Borouge and Borealis, plus planned acquisition of Nova Chemicals (ADNOC, novachem.com)
  
  
• Scale: described as a $60bn+ global polyolefins champion (ADNOC, novachem.com)
  
  
• Nova consideration: $13.4bn including debt (ADNOC, novachem.com)
  
  

Strategic rationale

• Build global scale in polyolefins with broader geographic footprint and integration benefits, including stronger positioning in North America via Nova. (ADNOC, novachem.com)
  
  
• This is “platform math”: capacity scale + feedstock position + commercial reach.
  
  

Multiple paid

• Nova Chemicals release notes the acquisition implies about 7.5x forward through-the-cycle EBITDA. (novachem.com)
  
  

Synergies and value creation levers

• The ADNOC release references a synergy target of $500m annual run-rate. (ADNOC)
  
  
• Execution levers typically include:
  
  
  
  • Global procurement
    
    
  • Manufacturing optimization and utilization management
    
    
  • Product slate upgrades and premium applications
    
    
  • Logistics and network efficiencies
    
    

Deal-specific risks

• Cycle risk: polyolefins spreads can swing hard
  
  
• Regulatory approvals across multiple jurisdictions
  
  
• Integration complexity across regions and legacy joint-venture structures
  
  

Case study 4: Covestro takeover offer by ADNOC (offer terms and positioning)

Snapshot

• Document date: investor presentation tied to the investment agreement and offer terms (2024) (Govestro AG)
  
  
• Buyer: ADNOC (through bidder structure referenced in Covestro materials)
  
  
• Target: Covestro
  
  
• Offer price: €62.00 per share, voluntary all-cash public takeover offer (Govestro AG)
  
  
• Premiums disclosed by Covestro: 54% premium to June 19, 2023 closing price and 21% premium to the June 2024 pre-announcement reference point described in the document. (Govestro AG)
  
  

Strategic rationale

• Buyer aims to step deeper into higher-value materials and global specialty chemicals capability, using Covestro as a platform rather than a bolt-on. (Govestro AG)
  
  

Multiple paid

• EV/EBITDA multiple is not stated in the Covestro investor presentation excerpted in the source. (Govestro AG)
  In practice, you would triangulate the implied valuation from offer price, shares outstanding, net debt, pension, and run-rate EBITDA, then adjust for cycle.
  
  

Synergies and value creation levers

• These deals are usually driven by:
  
  
  
  • Procurement and energy optimization at scale
    
    
  • Footprint and asset utilization improvements
    
    
  • Portfolio refocus toward advantaged product lines
    The materials document is focused on offer mechanics rather than detailed synergy disclosure. (Govestro AG)
    
    

Deal-specific risks

• Regulatory scrutiny and closing conditions (typical for large cross-border strategic transactions)
  
  
• Cycle timing: Covestro’s earnings sensitivity to macro and energy cost regimes
  
  

‍

One-Page Snapshot per Deal Template

‍

6. Valuation Framework & Modeling

How deals are priced in Materials & Chemicals

In this sector, you almost never win an IC memo (or a board discussion) by arguing a single method. The best work triangulates:

1. Trading comps (what similar public companies trade for)
   Use when:
   
   

• The target’s business mix is comparable to public peers
  
  
• Reporting is clean and margins are stable enough to normalize
  
  
• You want a quick reality check on implied valuation
  
  

Watch-outs in chemicals:

• One bad assumption about mid-cycle EBITDA can swing your implied multiple a lot
  
  
• Commodity exposure can make “cheap” comps look attractive right before spreads compress
  
  

2. Precedent transactions (what buyers actually paid)
   Use when:
   
   

• You’re valuing a niche with limited public comps (additives, coatings, catalysts, formulated specialties)
  
  
• Control premiums, scarcity, and synergy are the real story
  
  
• The buyer set is concentrated and behavior matters
  
  

Best practice:

• Separate strategic vs sponsor precedents
  
  
• Note whether the multiple is LTM, NTM, or “post-synergy”
  
  
• Be honest about disclosure quality (half the market prints “undisclosed” for a reason)
  
  

3. DCF (discounted cash flow)
   Use when:
   
   

• The business is a carve-out, a turnaround, or has a credible roadmap that comps don’t capture
  
  
• You need to show cash generation through a cycle (the board will ask)
  
  
• You want to test if the price still works when you take multiple expansion off the table
  
  

In chemicals, DCF is often the only method that forces discipline on:

• Working capital swings (inventory and receivables can eat your year)
  
  
• Capex reality (maintenance capex is not optional)
  
  
• Cycle normalization
  
  

‍

Typical control premiums

There isn’t a single “right” control premium. In practice it’s the outcome of:

• How competitive the process is
  
  
• How scarce the asset is
  
  
• How credible and bankable synergies are
  
  
• Whether the target is public (visible premium math) or private (often hidden in EBITDA adjustments)
  
  

If you’re building a model template, treat control premium as an output you can explain, not an input you assume.

‍

Key model drivers: what actually moves value

In Materials & Chemicals, value usually moves more from margin and cash discipline than from heroic growth. Three drivers dominate:

1. EBITDA margin path
   
   

• Pricing discipline and pass-through mechanics
  
  
• Mix upgrade (more specialty, more formulated, more service-like)
  
  
• Utilization and fixed-cost absorption
  
  
• Procurement and footprint actions
  
  

2. Working capital behavior
   
   

• How much inventory is required to support growth and service levels
  
  
• Payables power (supplier terms)
  
  
• Receivables discipline (especially in distribution)
  
  

3. Capex intensity
   
   

• Maintenance capex and plant reliability spend
  
  
• Debottlenecking and product quality upgrades
  
  
• Compliance and decarbonization-related spend
  
  

If your model is “working” but ignores working capital, it’s not working.

‍

Valuation framework: how analysts typically build the model stack

A clean deal model stack often looks like this:

Step 1: Normalize earnings

• Strip one-time items thoughtfully (not aggressively)
  
  
• Normalize energy/feedstock and pass-through where it’s defensible
  
  
• Sanity-check margins versus history and peer ranges
  
  

Step 2: Build standalone plan

• Revenue by end market and product family
  
  
• Price vs volume split
  
  
• Margin bridge (mix, pricing, costs, utilization)
  
  
• Capex and working capital policy
  
  

Step 3: Layer synergy cases

• Cost synergies by bucket with owner, timing, and one-time costs
  
  
• Revenue synergies only if you can explain the mechanism (and the sales cycle)
  
  
• Integration costs and dis-synergies (usually under-modeled)
  
  

Step 4: Value and test

• DCF (base, downside, upside)
  
  
• Exit multiple method
  
  
• Sensitivity tables
  
  
• Implied IRR / returns (for sponsor lens) or accretion/dilution (for strategic lens)

‍

Sample DCF Input Summary

Sensitivity Analysis Table

‍

7. Trends & Strategic Themes

The mood in Materials & Chemicals M&A has changed. A few years ago, big checks and big optimism were common. Today, buyers still have appetite, but it’s more selective, more operational, and way more tied to “show me the cash” logic. You can feel it in the deal mix: fewer trophy hunts, more focused transactions, more carve-outs, and a lot more scrutiny on downside risk. (BCG Global, Kearney, PwC)

‍

Sector-specific shifts that are driving deals

1. Portfolio simplification is back in style
   Large chemical companies are actively reshaping portfolios: selling subscale, cyclic, or non-core assets and redeploying into higher-return businesses. It’s not just a strategy slide anymore, it’s a deal pipeline. Advisory outlooks for 2026 flag carve-outs and divestitures as a central theme in US chemicals M&A. (Kearney, PwC)
   
   

What this looks like in the market:

• More corporate separations (often messy, often valuable)
  
  
• More “platform-ready” assets entering the market
  
  
• Fewer “conglomerate for its own sake” stories

2. Cost of capital is forcing honesty in underwriting
   Rates and financing conditions have pushed buyers to stop hand-waving. You see it in diligence depth, covenant sensitivity, and tighter comfort around mid-cycle EBITDA. BCG describes a shift away from megadeals toward more focused transactions in the tougher environment (mid-2023 through Q3 2025). (BCG Global)
   
   

Practically, this shows up as:

• More conservative base cases
  
  
• Stronger emphasis on cash conversion and working capital behavior
  
  
• “Synergy realism” becoming a gating item
  
  

3. Overcapacity and weak demand are pushing consolidation in basics
   Several 2026 outlooks describe persistent overcapacity and soft demand pressuring operating rates and margins in basic chemicals. That kind of environment tends to create two types of deals: consolidation (to rationalize capacity) and divestitures (to exit weaker positions). (Deloitte, McKinsey & Company)
   
   

Emerging models and what buyers are actually betting on

1. AI is showing up in diligence and operations, not as a buzzword badge
   In chemicals, “AI-enabled” is most useful where it improves speed and confidence:
   
   

• Diligence automation (contract and customer concentration, pricing waterfalls, clause extraction)
  
  
• Plant reliability and predictive maintenance
  
  
• Energy optimization and yield improvement
  
  

PwC’s 2026 chemicals deal outlook explicitly calls out AI-enabled diligence as part of the market conversation. (PwC)

Translation: buyers want better underwriting, faster, with fewer surprises.

2. Circular economy and recycling-linked plays are staying hot, but the bar is higher
   Circularity is still a strategic priority, but buyers are more demanding about economics:
   
   

• Feedstock reliability
  
  
• End-market willingness to pay for “circular” claims
  
  
• Capex intensity and operating complexity
  
  

McKinsey’s 2026 chemicals trends coverage continues to frame the sector’s need to adapt and find new value pools in a tougher reality, which is where circular models often sit. (McKinsey & Company)

3. Nearshoring and resilience are influencing where assets are built and bought
   Global trade dynamics, supply security, and customer proximity are nudging chemicals companies to rethink footprints. Advisory outlooks highlight reshoring and resilience as ongoing themes in US chemicals M&A. (PwC, Roland Berger)
   
   

What that tends to produce:

• Bolt-ons to deepen regional manufacturing and distribution
  
  
• Acquisitions that secure critical intermediates or additives closer to demand centers
  
  
• More attention to logistics and energy cost positioning
  
  

Antitrust and regulatory changes that matter for dealmaking

1. US merger review has become more demanding
   The FTC/DOJ Merger Guidelines issued December 18, 2023 outline the agencies’ analytical frameworks and enforcement posture. In plain terms: higher scrutiny, more focus on competitive effects, and a tougher environment for consolidation in already concentrated niches. (Federal Trade Commission, justice.gov)
   
   

How it hits chemicals specifically:

• Local and product-market definitions can get narrow fast (especially in specialty categories)
  
  
• Customers and switching costs become central in the narrative
  
  
• Remedy strategy needs to be considered earlier, not as a closing footnote
  
  

2. PFAS regulation is a live wire across Europe
   The PFAS conversation is not academic anymore. ECHA has published an updated PFAS restriction proposal under REACH, reflecting ongoing work since the initial submission in January 2023. (European Chemicals Agency)
   
   

Why this matters for M&A:

• Liabilities and remediation risk can move from “note” to “deal breaker”
  
  
• Certain product lines become stranded or require reformulation investment
  
  
• Buyers increasingly ask for deeper product-level chemical inventories and exposure mapping
  
  

Even high-level news coverage has emphasized the potential economic implications and the policy momentum around restrictions. (Financial Times, Le Monde.fr)

‍

Expert POV: the story underneath the story

Here’s the simplest way to say what’s happening: chemicals M&A is moving from “scale for scale” to “precision for resilience.”

• Specialties: buyers are paying for durability. Pricing power, formulation know-how, and customer stickiness are the new luxury goods.
  
  
• Basics: buyers are paying for position. Lowest-cost assets and advantaged feedstock win the cycle; everyone else needs a plan.
  
  
• Carve-outs: complexity is the opportunity. The messier the separation, the more room for an operator (or sponsor) who can execute.

‍

Timeline of Trend Emergence

‍

8. 2025–26 Market Outlook

This outlook is written for February 2026. It’s meant to help readers understand what’s likely to shape deal flow in Materials & Chemicals over the next 6–18 months. It is not investment advice.

‍

Expected M&A drivers

1. Portfolio reshaping will keep feeding the pipeline
   Corporate carve-outs and divestitures are still the cleanest source of actionable deals, especially in chemicals where conglomerates are pruning non-core, subscale, or more cyclical units. PwC’s Chemicals US Deals 2026 Outlook leans hard into this theme and ties it to reshoring, resilience, and sharper portfolio focus. (PwC)
   
   

What that means in practice:

• More standalone packages coming to market
  
  
• More sponsor interest (carve-outs are where operational skill gets paid)
  
  
• More corporate buyers stepping in selectively for bolt-ons that upgrade mix
  
  

2. Sponsor “dry powder” meets real pressure to exit
   Private equity has capital to deploy, but the bigger driver in 2026 is the need to move aging portfolios and show realizations. You should expect more sponsor-to-sponsor deals, more partial exits, and more creative structures (continuation vehicles, minority sales) when full exits don’t pencil cleanly. FMI’s 2026 outlook points to sponsor dynamics and valuation trends as central to the 2026 setup. (FMI Corp.)
   
   
3. Operating stress in basic chemicals will force moves
   Multiple 2026 industry outlooks describe a prolonged downcycle with soft demand and overcapacity pressuring utilization and margins, especially in basic chemicals. Deloitte notes forecasts for global chemical production growth falling to around 2% for 2026 and highlights the persistent downcycle dynamics. (Deloitte)
   Fitch also flagged massive overcapacity and trade tension as drivers behind a “deteriorating” outlook, while noting restructuring could help rebalance markets over time. (Fitch Ratings)
   
   

This is the environment where you typically see:

• Consolidations to rationalize capacity
  
  
• Divestitures of weaker assets
  
  
• Restructurings and plant actions that precede asset sales
  
  

4. “AI in dealmaking” moves from hype to table stakes
   The practical adoption isn’t flashy. It’s about speed and confidence: faster screening, tighter diligence, cleaner integration planning. PwC explicitly calls out AI-enabled diligence in the sector outlook, and BCG’s broader dealmaking work describes using AI/advanced analytics across target identification, diligence, and integration. (PwC, BCG Global)
   
   

Expected headwinds

1. Uncertainty is still the tax on valuation
   Even with deal volumes improving in some parts of the market, 2026 confidence is described as measured because macro and geopolitical uncertainty persists. That tends to widen bid-ask spreads and slow processes. (BCG Global)
   
   
2. Europe remains a tougher operating backdrop
   High energy costs and competitiveness concerns continue to weigh on European chemicals. Recent reporting highlighted a steep drop in new chemicals investment and ongoing closures, reinforcing why some companies are pulling back or reshaping footprints. (Financial Times)
   
   
3. Regulatory complexity stays elevated
   Antitrust and chemical-specific regulatory exposures (like PFAS and other product restrictions) can change the risk profile of a target quickly, which matters for diligence scope and deal certainty. (This theme is also echoed across the 2026 outlooks emphasizing uncertainty and complexity.) (BCG Global, PwC)
   
   

Buy-side vs sell-side predictions

Buy-side (strategics)

• Preference for bolt-ons that improve product mix, pricing power, or customer stickiness (specialty, coatings, formulation-heavy niches).
  
  
• More willingness to buy carve-outs if the package comes with a credible separation plan and clean financials.
  
  
• In basics, interest concentrates around advantaged-cost assets and platforms where integration can genuinely change the cost curve (not just “scale”). This links directly to the overcapacity story highlighted by Deloitte/Fitch. (Deloitte, Fitch Ratings)
  
  

Buy-side (sponsors)

• More carve-out hunting and “fix-and-build” strategies, especially where working capital, procurement, and footprint changes can unlock value.
  
  
• More structured deals when full leverage doesn’t work (earnouts, seller notes, minority stakes, JV structures).
  
  
• More urgency around exits, driving sponsor-to-sponsor activity and creative liquidity solutions. (FMI Corp.)
  
  

Sell-side (corporates)

• More divestitures of non-core or underutilized assets to fund capex where it matters (reliability, decarb, automation) and to simplify stories for investors. (PwC)
  
  
• More “dual-track” thinking (sale vs IPO vs JV) for higher-quality assets, depending on market windows.

‍

Funnel of Deal Types by Strategic Priority

Outlook Grid: Short / Mid / Long Term

‍

9. Appendices & Citations

This section does three things:

1. Provides structured deal data for reference
   
   
2. Lists primary sources used in the report
   
   
3. Explains methodology and limitations
   
   

Everything below is structured so it can be lifted directly into slides, an appendix PDF, or exported into CSV.

‍

Deal Tables

Methodology

1. Sources
   This report incorporates publicly available information including:

• Company press releases and investor presentations
• Industry outlooks (PwC Chemicals US Deals Outlook, Deloitte Chemical Industry Outlook, BCG Chemicals M&A publications, FMI Chemicals & Materials M&A Outlook)
• Regulatory publications (FTC Merger Guidelines 2023; ECHA PFAS proposal updates)
• Financial press reporting (Financial Times)

2. Approach to multiples

• Trading multiples are referenced using LTM or NTM where disclosed.
• Transaction multiples reflect public statements and may vary depending on synergy inclusion.
• Mid-cycle normalization assumptions applied where relevant for cyclically exposed segments.

3. DCF framework assumptions

• Free Cash Flow to Firm (FCFF) model structure
• WACC ranges based on sector risk, leverage, and cyclicality
• Terminal growth anchored to long-term GDP/inflation ranges (typically 1.5%–3.0%)
• Sensitivity analysis used to illustrate valuation dispersion

4. Limitations

• This is a strategic industry research report, not a fairness opinion.
• Certain private transaction financials are not publicly disclosed.
• Market conditions and valuation levels change rapidly.
• No forward-looking guarantee of performance.

‍

Data Sources (Hyperlinked)

Industry & Advisory Outlooks
PwC – Chemicals US Deals 2026 Outlook
https://www.pwc.com/us/en/industries/industrial-products/library/chemicals-deals-outlook.html

Deloitte – 2026 Chemical Industry Outlook
https://www.deloitte.com/us/en/insights/industry/chemicals-and-specialty-materials/chemical-industry-outlook.html

BCG – Chemicals M&A Publications
https://www.bcg.com/publications/2025/from-megadeals-to-focused-transactions-in-chemicals

FMI – Chemicals & Materials M&A Recap & 2026 Outlook
https://fmicorp.com/insights/thought-leadership/chemicals-and-materials-ma-recap-2026-outlook

Regulatory
FTC – 2023 Merger Guidelines
https://www.ftc.gov/system/files/ftc_gov/pdf/P234000-NEW-MERGER-GUIDELINES.pdf

ECHA – PFAS Restriction Updates
https://echa.europa.eu

Company Releases (Examples Referenced)
Honeywell – JM Catalyst Technologies Acquisition
https://www.honeywell.com

BASF – Coatings Transaction
https://www.basf.com

ADNOC – Polyolefins Platform Announcement
https://www.adnoc.ae

Covestro – Investor Presentation (ADNOC Offer)
https://www.covestro.com

Sherwin-Williams – BASF Brazil Acquisition
https://investors.sherwin-williams.com

‍

Disclaimer: The information on this page is provided by MergersandAcquisitions.net for general informational purposes only and does not constitute financial, investment, legal, tax, or professional advice, nor an offer or recommendation to buy or sell any security, instrument, or investment strategy. All content, including statistics, commentary, forecasts, and analyses, is generic in nature, may not be accurate, complete, or current, and should not be relied upon without consulting your own financial, legal, and tax advisers. Investing in financial services, fintech ventures, or related instruments involves significant risks—including market, liquidity, regulatory, business, and technology risks—and may result in the loss of principal. MergersandAcquisitions.net does not act as your broker, adviser, or fiduciary unless expressly agreed in writing, and assumes no liability for errors, omissions, or losses arising from use of this content. Any forward-looking statements are inherently uncertain and actual outcomes may differ materially. References or links to third-party sites and data are provided for convenience only and do not imply endorsement or responsibility. Access to this information may be restricted or prohibited in certain jurisdictions, and MergersandAcquisitions.net may modify or remove content at any time without notice.

‍